Treatment of Established Status Epilepticus in the Elderly - a prospective, randomized, double-blind comparative effectiveness trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516634-35-00

Acronym

ToSEE

Enrollment

132

Registered

2024-10-11

Start date

2024-02-01

Completion date

Unknown

Last updated

2025-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Convulsive or nonconvulsive benzodiazepine-resistant (established) status epilepticus (eSE) in people 65 years or older

Brief summary

Primary endpoint is the effectiveness of intravenous valproate (VPA) or levetiracetam (LEV) to terminate eSE and maintain control of epileptic activity up to 60 minutes after initiation of the trial intervention

Interventions

DRUGVALPROIC ACID

DRUGLEVETIRACETAM

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary endpoint is the effectiveness of intravenous valproate (VPA) or levetiracetam (LEV) to terminate eSE and maintain control of epileptic activity up to 60 minutes after initiation of the trial intervention	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026